Subcutaneous Immunoglobulin Therapy FAQs

Frequently asked questions about cutaquig

General FAQs about cutaquig

FAQs about self-administering cutaquig

FAQs about IG products

What is Primary Immunodeficiency?

Learn more about PI

  1. Cutaquig Full Prescribing Information. Paramus, NJ: Octapharma; rev October 2021.
  2. Berman K. Safety, Efficacy, Tolerability, Advantages and Disadvantages of Intravenous and Subcutaneous Immune Globulin Therapy. Highlights from IG Living Teleconference. December 10, 2015. Accessed April 25, 2019.
  3. Clinical Study Report SCGAM-01. Clinical Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability and safety of subcutaneous human immunoglobulin (octanorm 16.5%) in patients with primary immunodeficiency diseases. NCT01888484. June 2018. Accessed May 2, 2019.
  4. Kobayashi RH, Gupta S, Melamed I, et al. Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies. Front Immunol. 2019;10(40):1-12.
  5. McCormack PL. Immune globulin subcutaneous (human) 20% in primary immunodeficiency disorders. Drugs. 2012;72(8):1087-1097.
  6. Kobrynski L. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics. 2012;6:277-287.